[Therapy of malignant non-Hodgkin's lymphoma].
Up to now the results of the therapy of malignant non-Hodgkin lymphomas are not satisfactory. In order to improve these results decisively it is necessary to develop and to test therapeutic strategies on standardised diagnostic basis. On the basis of the histological classification after Kiel of the malignant non-Hodgkin lymphomas and the clinical stage subdivision of the lympho-granulomatosis after Rye (for the malignant non-Hodgkin lymphomas modified by Musshoff) in the present paper therapeutic recommendations are given which are based on proved therapeutic regimes.
D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007278:Injections, Spinal; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D009367:Neoplasm Staging; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D002699:Chlorambucil; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D008727:Methotrexate
Die Therapie der malignen Nicht-Hodgkin-Lymphome.